Concepedia

Author

Dheepak Kanagavel

Sanofi (France)ORCID

Also Known As

D Kanagavel, D. Kanagavel, Dheepak Kanagavel

30

Publications

321

Citations

9

H-Index

15

Concepts

All Affiliations

Sanofi (France)Sanofi (United States)Harvard UniversityMassachusetts General HospitalInstitut Gustave Roussy
DK

About

Dheepak Kanagavel is an author at Sanofi (France) specializing in radiation oncology, medicine, and oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

3

3

95

2

Pathology

2

2

75

3

Health Sciences

1

1

20

4

Gastroenterology

1

1

63

5

Immunology

1

1

20

Dheepak Kanagavel

×

8

Publications

257

Citations

8

H-Index

YearCitations

A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma

Joseph Mıkhael, Paul G. Richardson, Saad Z. Usmani,

Blood

2019

88

A prognostic model in patients treated for metastatic gastric cancer with second-line chemotherapy

Dheepak Kanagavel, M. Yu. Fedyanin, A. Tryakin,

Annals of Oncology

2010

63

AMEERA-5: a randomized, double-blind phase 3 study of amcenestrant plus palbociclib <i>versus</i> letrozole plus palbociclib for previously untreated ER+/HER2– advanced breast cancer

Aditya Bardia, Javier Cortés, Sara A. Hurvitz,

Therapeutic Advances in Medical Oncology

2022

28

Preliminary Results from a Phase I Study of Isatuximab (ISA) in Combination with Bortezomib, Lenalidomide, Dexamethasone (VRd), and in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Non-Eligible for Transplant

Enrique M. Ocio, Paula Rodríguez‐Otero, Sara Bringhen,

Blood

2018

22

Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma

Saad Z. Usmani, Chatchada Karanes, William Bensinger,

Leukemia

2021

20

Randomized Phase III Study of Amcenestrant Plus Palbociclib Versus Letrozole Plus Palbociclib in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Primary Results From AMEERA-5

Javier Cortés, Sara A. Hurvitz, Joyce O’Shaughnessy,

Journal of Clinical Oncology

2024

14

Paclitaxel + BEP (T-BEP) Regimen as Induction Chemotherapy in Poor Prognosis Patients With Nonseminomatous Germ Cell Tumors: A Phase II Study

A. Tryakin, M. Fedyanin, Dheepak Kanagavel,

Urology

2011

12

A Phase Ib Study of Isatuximab in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone (VCDI) in Patients with Newly Diagnosed Multiple Myeloma Non-Eligible for Transplantation

Enrique M. Ocio, Sara Bringhen, Stefania Oliva,

Blood

2017

10

Page 1